a biotech company designing antimicrobial peptides

Introducing The First Real Solution

to fighting antibiotic-resistant bacteria

Partner With Us
AMP Discovery Logo
Menu

Who WE Are

AMP Discovery, LLC is an emerging life science company focused on the development and commercialization of proprietary antimicrobial peptides (AMPs) as therapeutic solutions for the treatment of systemic infectious diseases caused by Gram-negative bacteria, including antibiotic-resistant Gram-negative bacteria.

Why it Matters

we are facing a worldwide re-emergence of infectious diseases threatening the world with return to the pre-antibiotic era.

There are now “Superbugs” that are resistant to most or all available antibiotics, including antibiotics of last resort. If proactive solutions are not quickly found to slow the rate of drug resistance, it has been estimated that by 2050, ten million lives a year will be at risk. Currently, 700,000 people die every year from drug resistant strains of common bacterial infections, HIV, TB and malaria. Even in developed countries such as the United States, each year about 2 million people become infected with antibiotic-resistant bacteria resulting in at least 23,000 deaths annually. A conservative estimate for the global marketplace for healthcare-associated infections (HAIs) caused by Gram-negative bacteria across the seven major pharmaceutical markets is projected to exceed US$3.6 billion in sales by 2026.

How We're Different

Our de novo rational design platform has produced a large portfolio of D-conformation, α-helical antimicrobial peptides that are structurally manipulated to alter their hydrophobicity and amphipathicity properties. Positively charged substitutions and structural alterations on both the polar and non-polar faces of our peptides produce a unique “carpet model” mechanism of action. Our membrane-discriminate peptides are:

AMP Mark Icon

Membrane
Targeted

We deploy positive charge substitution on the non-polar face (“specificity determinants”) to facilitate cytoplasmic membrane selectivity for Gram-negative prokaryotic organisms.

AMP Mark Icon

Toxicity
Eliminated

Our discovery of specificity determinants coupled with substitution of unusual charged amino acids (Dab and Dap) on the polar face eliminates toxicity towards eukaryotic cells as determined by the most stringent conditions of hemolysis of human red blood cells. Such results are unprecedented in AMP research.

AMP Mark Icon

Half-Life
Prolonged

Unlike L-conformation forms, our D-conformation peptides are resistant to proteolytic enzymes, providing extended circulating half-lives.

AMP Mark Icon

Decreased Binding
To Serum Proteins

Specificity determinants prevent any significant loss of antimicrobial activity in the presence of serum proteins and prevent binding to serum proteins.

AMP Mark Icon

No Resistance
Development

Since the sole target of our AMPs is the cytoplasmic membrane of bacteria, the development of resistance is highly unlikely.

Research Team

Robert Hodges Headshot

Robert Hodges, Ph.D., FRSC

Founder & CSO

Professor of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, John Stewart Endowed Chair in Peptide Chemistry. In 2017 received the most prestigious award in peptide chemistry, the Bruce Merrifield Award, for outstanding lifetime accomplishment in peptide research recognizing the highest level of scientific creativity. Prior experience, Director and CEO of the Protein Engineering Network of Centers of Excellence; S.P.I. Synthetic Peptides, Inc.; Cytovax Biotechnologies, Inc.; BioAMPs International, Inc. and PeptiVir, Inc.

Lajos Gera Headshot

Lajos Gera, Ph.D

Expert in Organic and Peptide Chemistry

Research Associate Professor in Biochemistry and Molecular Genetics, University of Colorado School of Medicine. Expert in Organic and Peptide Chemistry. Prior experience, Breceptin, B9870 cytolytic bradykinin antagonist peptide dimer drug development, which was approved by the Food and Drug Administration (FDA) on December 4, 2009 (IND 107,125) to proceed to clinical trial by Apoplogic Pharmaceuticals for the treatment of lung cancer.

Colin Mant Headshot

Colin Mant, Ph.D.,

Director of Analytical Chemistry

Worked with Dr. Hodges for over 35 years, both at the University of Alberta and the University of Colorado, School of Medicine. Outstanding achievements in the area of high-performance liquid chromatography and biochemistry.

Contact Us
X
AMP Discovery Logo